| NIPPON ZENYAKU KOGYO CO., LTD. Patent applications |
| Patent application number | Title | Published |
|---|
| 20110091490 | NOVEL VACCINE FOR DOG - This invention provides vaccines against canine distemper virus infections, canine adenovirus type 2 infections, and canine parvovirus infections that can be orally administered. The invention also provides the attenuated canine distemper virus strain obtained by adapting the canine distemper virus 95-54 strains in cultured cells to attenuate the same, the attenuated canine adenovirus type 2 strain obtained by adapting the canine adenovirus type 2 F1 strain in cultured cells to attenuate the same, and an attenuated canine parvovirus strain obtained by adapting the canine parvovirus F3 strain in cultured cells to attenuate the same. | 04-21-2011 |
| 20100247568 | NOVEL ADJUVANT - The present invention provides a vaccine adjuvant composition which is used in combination with an allergen vaccine, infection vaccine or tumor vaccine. The present invention specifically provides a vaccine adjuvant composition comprising hemozoin or β-hematin and being used in combination with an allergen vaccine, infection vaccine or tumor vaccine, and a vaccine composition comprising the vaccine adjuvant composition and an allergen vaccine, infection vaccine or tumor vaccine | 09-30-2010 |
| 20090181121 | Feedstuff and method for supply of gamma-aminobutyric acid - γ-Aminobutyric acid is supplied to animal efficiently and inexpensively to effectively enhance stress-relieving effect on the animal. | 07-16-2009 |
| 20090142830 | Aqueous Solution for Cell Preservation - To provide an aqueous solution for cell preservation which is free of a natural animal-derived component such as a basal medium or serum. An aqueous preservation solution showing a high cell survival rate was obtained by removing a natural animal-derived component such as a basal medium or serum and controlling other components and their concentrations. | 06-04-2009 |
| 20090005448 | Injection for Mastitis - Disclosed is infusion for mastitis which contains a main ingredient, medium-chain fatty acid monoglyceride and an oily base wherein diffusivity and dispersivity of the main ingredient are improved by the monoglyceride to enhance dissolubility and thus absorbency of the main ingredient. In comparison with conventional infusions for mastitis, the infusion has immediate effectivity and is short in residual term; the main ingredient is expected to be utilized effectively and without waste. | 01-01-2009 |
